Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Lithium is considered by many as the gold standard medication in the management of bipolar disorder (BD). However, the clinical response to lithium is heterogeneous, and the molecular basis for this difference in response is unknown. In the present study, we sought to determine how the peripheral blood gene expression profiles of patients with bipolar disorder (BD) changed over time following intitiation of treatment with lithium, and whether differences in those profiles over time were related to the clinical response.
Pubmed ID: 22967286
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
A portal to biomedical and genomic information. NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease.
View all literature mentionsA multiple question assessment scale used to provide an indication of depression and serves as a way to evaluate recovery in patients. It is designed for adults and is used to rate the severity of their depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. It was designed to be administered by a trained professional using a semi-structured interview. Although Hamilton's original scale had 17 items, other versions were developed to include up to 29 items (HRSD-29).(Adapted from Wikipedia) It takes about 20 minutes to complete the interview and score the results. Scoring: * 0-7 Normal * 8-13 Mild * 14-18 Moderate * 19-22 Severe * > or = 23 Very Severe
View all literature mentions